DCPHDeciphera Pharmaceuticals Inc

$55.54
$-2.90 (-5%)

Deciphera Pharmaceuticals Inc (DCPH) Stock Analysis

Create a FREE Account to View Full DCPH Stock Report

Deciphera Pharmaceuticals Inc (DCPH) Analyst Forecast

Next 12 months ➝Current Price$55.5452-week High$71.1152-week Low$19.88MEAN$64.73+16.54%HIGH$84.00+51.24%LOW$48.00-13.58%
  • Last Price$55.54
  • Previous Close$58.44
  • Change $-2.90
  • Open$54.50
  • Volume2,616,897
  • Avg. Volume (100-day)530,874
  • Market Capitalization$2.83B
  • Days Range $53.39 - $56.24
  • 52-week Range $19.88 - $71.11
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-3.95
  • Earnings Date03/12/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta1.626
  • PEG Ratio
  • Volatility0.76
  • Average True Range0.05
Deciphera Pharmaceuticals Inc is a biotechnology company, develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib.